Sartorius Aktiengesellschaft (ETR: SRT3)
Market Cap | 12.98B |
Revenue (ttm) | 3.32B |
Net Income (ttm) | 77.20M |
Shares Out | 69.04M |
EPS (ttm) | n/a |
PE Ratio | n/a |
Forward PE | 65.90 |
Dividend | 0.74 (0.36%) |
Ex-Dividend Date | n/a |
Volume | 72,481 |
Open | 209.80 |
Previous Close | 209.00 |
Day's Range | 203.70 - 211.20 |
52-Week Range | 199.50 - 383.70 |
Beta | 0.93 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | Jan 28, 2025 |
About SRT3
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quar... [Read more]
Financial Performance
In 2023, SRT3's revenue was 3.40 billion, a decrease of -18.66% compared to the previous year's 4.17 billion. Earnings were 205.20 million, a decrease of -69.74%.
Financial StatementsNews
Betting on Growth: 4 Favorite Stocks From T. Rowe Price's Peter Bates
The manager of the Global Select Equity Strategy looks for high margins, cash generation, competitive advantages, and a long runway of growth.
Sartorius Aktiengesellschaft (SARTF) Q3 2024 Earnings Call Transcript
Sartorius Aktiengesellschaft reports nine-month results
Strong Nine-Month Results: Sales Steady, Orders Up, Profit & Cash Flow Rise
Sartorius AG's latest financial results reveal a mixed performance, with a slight dip in sales but a boost in order intake. The company remains optimistic, confirming its outlook for 2024. Jetzt den v...
EQS-News: Nine-month results in line with expectations: sales revenue almost at prior-year level; orders on the rise; robust profitability; increased cash flow
EQS-News: SARTORIUS AG / Key word(s): 9 Month figures Nine-month results in line with expectations: sales revenue almost at prior-year level; orders on the rise; robust profitability; increased cash f...
'We are in a year of transition,' says Sartorius CEO
Sartorius CEO Joachim Kreuzburg discusses the pharmaceutical industry and his business outlook.
Sartorius Aktiengesellschaft (SARTF) Q1 2024 Earnings Call Transcript
Sartorius Aktiengesellschaft (OTCPK:SARTF) Q1 2024 Earnings Conference Call April 18, 2024 7:00 AM ET Corporate Participants Dr. Joachim Kreuzburg - Chairman René Fáber - Chief Executive Officer Flori...
Sartorius Aktiengesellschaft (SARTF) Q4 2023 Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) Q4 2023 Earnings Call Transcript
10 stocks for investors looking for ‘wonderful companies at a fair price'
As money managers talk about various methods of selecting quality companies, investors might also think about diversification, which can lower risk and broaden opportunities.
These 5 DAX index companies are in trouble as their stocks plunge
German stocks are not doing well as the economy goes through substantial challenges. The most recent data showed that business confidence has tumbled while manufacturing and services PMIs have remaine...
Sartorius Aktiengesellschaft (SARTF) Q2 2023 Earnings Call Transcript
Sartorius Aktiengesellschaft (OTCPK:SARTF) Q2 2023 Earnings Conference Call July 21, 2023 9:30 AM ET Company Participants Joachim Kreuzburg - Chairman of the Executive Board and Chief Executive Office...
Sartorius: A German Champion With A Discounted Price
Sartorius has been experiencing a demand decline since 2022. Sartorius serves a niche market, which gives it a strong moat. Sartorius benefits from the long-term tailwinds of its sector.
Sartorius Aktiengesellschaft (SARTF) Q1 2023 Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) Q1 2023 Earnings Call Transcript.
Sartorius, Sartorius Stedim shares fall after Polyplus acquisition
Shares in German pharmaceutical and laboratory equipment supplier Sartorius AG and its France-listed subsidiary Sartorius Stedim Biotech SA DIM, -6.51% fell in opening trade on Friday after the compan...
Sartorius AG: Combating And Benefiting From Eroom's Law
Sartorius is a low volume, almost private business, but offers investors exposure to great fundamentals in healthcare. With qualities that separate them from larger peers, Sartorius may offer a better...
Sartorius Aktiengesellschaft (SARTF) Q4 2022 Earnings Call Transcript
Sartorius Aktiengesellschaft (OTCPK:SARTF) Q4 2022 Earnings Conference Call January 26, 2023 9:30 AM ET Company Participants Joachim Kreuzburg - Chairman of Exec. Board & CEO Rainer Lehmann - CFO, Mem...
Sartorius Aktiengesellschaft (SARTF) Q3 2022 Earnings Call Transcript
Sartorius Aktiengesellschaft (OTCPK:SARTF) Q3 2022 Earnings Conference Call October 19, 2022 9:30 AM ET Corporate Participants Joachim Kreuzburg - Chief Executive Officer Rainer Lehmann - Chief Financ...
Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q2 2022 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (OTCPK:SARTF) Q2 2022 Earnings Conference Call July 21, 2022 9:30 AM ET Company Participants Joachim Kreuzburg - Chief Executive Officer Rainer Lehmann - Chief Financial O...
Sartorius AG: Buy The French Subsidiary Instead
Sartorius AG and Sartorius Stedim are a buy after a significant drawdown. Sartorius is operating in the fast-growing biopharmaceutical industry.
Sartorius AG (SARTF) CEO Joachim Kreuzburg on Q1 2022 Results - Earnings Call Transcript
Sartorius AG ( OTCPK:SARTF) Q1 2022 Results Conference Call April 21, 2022 9:30 AM ET Company Participants Joachim Kreuzburg - CEO Rainer Lehmann - CFO Conference Call Participants Delphine Le Louet ...
Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q4 2021 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q4 2021 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q3 2021 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q3 2021 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) CEO Dr. Joachim Kreuzburg on Q2 2021 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) CEO Dr. Joachim Kreuzburg on Q2 2021 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q1 2021 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q1 2021 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q4 2020 Results - Earnings Call Transcript
Sartorius Aktiengesellschaft (SARTF) CEO Joachim Kreuzburg on Q4 2020 Results - Earnings Call Transcript